Product Brief:
Theory:
The receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S protein) initiates cell membrane fusion by binding to the host angiotensin converting enzyme 2 (ACE2) cell receptor and infects the human body. Neutralizing antibodies can block the binding process of S-RBD and ACE2, thereby preventing the virus from contacting the host cell, and ultimately preventing virus infection.
Application:
SARS-CoV-2 NAbs assay can be used for the evaluation the titer of neutralizing antibody in human body
It is a valuable tool in measuring the effectiveness of vaccines and help evaluate the status of broad vaccination programs
